Gene therapy for hemophilia: Advancing beyond the first clinical success

Current Opinion in Hematology

Volumn 20, Issue 5, 2013, Pages 410-416

  Monahan, Paul E ^a   Gui, Tong ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

adeno associated virus; factor IX; factor VIII; gene therapy; hemophilia

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BORTEZOMIB; DOUBLE STRANDED DNA; LENTIVIRUS VECTOR; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; PREDNISOLONE;

ADAPTIVE IMMUNITY; ADENO ASSOCIATED VIRUS; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); GENE TARGETING; GENE THERAPY; HEMOPHILIA; HEMOPHILIA B; HEMOPHILIC ARTHROPATHY; HEPATITIS; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; MEMORY T LYMPHOCYTE; MESENCHYMAL STEM CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; SEROTYPE; TRANSGENE; VIRUS CAPSID;

CLINICAL TRIALS AS TOPIC; DEPENDOVIRUS; FACTOR IX; GENETIC THERAPY; GENETIC VECTORS; HEMOPHILIA B; HUMANS;

EID: 84883263808     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328363c1a1     Document Type: Review

References (64)

1. Tagliaferri A, Di Perna C, Riccardi F, et al. The natural history of mild haemophilia: a 30-year single centre experience. Haemophilia 2012; 18: 166-174.
2. Anson DS, Hock RA, Austen D, et al. Towards gene therapy for hemophilia B. Mol Biol Med 1987; 4:11-20.
3. Walsh CE, Batt KM. Hemophilia clinical gene therapy: brief review. Transl Res 2013; 161:307-312.
4. O'Reilly M, Kohn DB, Bartlett J, et al. Gene therapy for rare diseases: summary of a National Institutes of Health workshop, September 13, 2012. Hum Gene Ther 2013; 24:355-362.
5. Testa F, Maguire AM, Rossi S, et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with leber congenital amaurosis type 2. Ophthalmology 2013; 120:1283-1291.
6. Leone P, Shera D, McPhee SW, et al. Long-term follow-up after gene therapy for canavan disease. Sci Transl Med 2012; 4:1-13.
7. Kastelein JJ, Ross CJ, Hayden MR. From mutation identification to therapy: discovery and origins of the first approved gene therapy in the Western world. Hum Gene Ther 2013; 24:472-478.
8. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365:2357-2365.
9. Li C, Narkbunnam N, Samulski RJ, et al. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Ther 2012; 19:288-294.
10. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12:342-347.
11. Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 2013. [Epub ahead of print] A comprehensive and up-to-date review of innate and adaptive cell-mediated and humoral immune observed in adeno-associated virus clincal and nonclinical applications.
12. Nathwani AC, Gray JT, McIntosh J, et al. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 2007; 109:1414-1421.
13. Wu Z, Sun J, Zhang T, et al. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther 2008; 16:280-289.
14. Calcedo R, Morizono H, Wang L, et al. Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine Immunol 2011; 18:1586-1588.
15. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 2001; 8:1248-1254.
16. McCarty DM, Fu H, Monahan PE, et al. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 2003; 10:2112-2118.
17. Allay JA, Sleep S, Long S, et al. Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. Hum Gene Ther 2011; 22:595-604.
18. den Uijl IE, Fischer K, Van Der Bom JG, et al. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia 2011; 17:41-44.
19. den Uijl I, Biesma D, Grobbee D, et al. Turning severe into moderate haemophilia by prophylaxis: are we reaching our goal? Blood Transfus 2012. [Epub ahead of print]
20. Ljung R, Auerswald G, Benson G, et al. Novel coagulation factor concentrates: Issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients. Haemophilia 2013. [EPUB ahead of print] PMID 23387528.
21. Monahan PE, Sun J, Gui T, et al. Employing factor IX variants to avoid limitations imposed by immune recognition of AAV vector in hemophilia B gene therapy. Blood 2011; 118:1350.
22. Grieger JC, Samulski RJ. Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol 2012; 507:229-254.
23. Simioni P, Tormene D, Tognin G, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med 2009; 361:1671-1675.
24. Finn JD, Nichols TC, Svoronos N, et al. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. Blood 2012; 120:4521-4523.
25. Cantore A, Nair N, Della Valle P, et al. Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. Blood 2012; 120:4517-4520.
26. Kao CY, Yang SJ, Tao MH, et al. Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in vitro and in vivo. Thromb Haemost 2013. [Epub ahead of print]
27. Zhong L, Li B, Mah CS, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A 2008; 105:7827-7832.
28. Monahan PE, Lothrop CD, Sun J, et al. Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Mol Ther 2010; 18:1907-1916.
29. Martino AT, Basner-Tschakarjan E, Markusic DM, et al. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 2013; 121:2224-2233.
30. Sen D, Gadkari RA, Sudha G, et al. Targeted modifications in adenoassociated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo. Hum Gene Ther Methods 2013; 24:104-116.
31. Wang L, Calcedo R, Bell P, et al. Impact of preexisting immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther 2011; 22:1389-1401.
32. Monteilhet V, Saheb S, Boutin S, et al. A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol Ther 2011; 19:2084-2091.
33. Mingozzi F, Chen Y, Edmonson SC, et al. Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue. Gene Ther 2013; 20:417-424.
34. Li C, Diprimio N, Bowles DE, et al. Single amino acid modification of adenoassociated virus capsid changes transduction and humoral immune profiles. J Virol 2012; 86:7752-7759.
35. Nathwani AC, Rosales C, McIntosh J, et al. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther 2011; 19:876-885.
36. Niemeyer GP, Herzog RW, Mount J, et al. Long-term correction of inhibitorprone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood 2009; 113:797-806.
37. Buchlis G, Podsakoff GM, Radu A, et al. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood 2012; 119:3038-3041.
38. Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101:2963-2972.
39. Chao H, Monahan PE, Liu Y, et al. Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. Mol Ther 2001; 4:217-222.
40. Wang L, Louboutin JP, Bell P, et al. Muscle-directed gene therapy for hemophilia B with more efficient and less immunogenic AAV vectors. J Thromb Haemost 2011; 9:2009-2019.
41. Sarkar R, Tetreault R, Gao G, et al. Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood 2004; 103:1253-1260.
42. Sabatino DE, Lange AM, Altynova ES, et al. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. Mol Ther 2011; 19:442-449.
43. Grieger JC, Samulski RJ. Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J Virol 2005; 79:9933-9944.
44. Mclntosh J, Lenting PJ, Rosales C, et al. Therapeutic level of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood 2013; 121:3335-3344.
45. Siner JI, Iacobelli NP, Sabatino DE, et al. Minimal modification in the factor VIII B domain sequence ameliorates the murine hemophilia A phenotype. Blood 2013; 121:4396-4403.
46. Sack BK, Merchant S, Markusic DM, et al. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy. PLoS One 2012; 7:e37671.
47. Finn JD, Ozelo MC, Sabatino DE, et al. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood 2010; 116:5842-5848.
48. Mingozzi F, Liu YL, Dobrzynski E, et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 2003; 111:1347-1356.
49. Matrai J, Cantore A, Bartholomae CC, et al. Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk. Hepatology 2011; 53:1696-1707.
50. Hyland KA, Olson ER, Clark KJ, et al. Sleeping Beauty-mediated correction of Fanconi anemia type C. J Gene Med 2011; 13:462-469.
51. Chavez CL, Keravala A, Chu JN, et al. Long-term expression of human coagulation factor VIII in a tolerant mouse model using the phiC31 integrase system. Hum Gene Ther 2012; 23:390-398.
52. Ellis BL, Hirsch ML, Porter SN, et al. Zinc-finger nuclease-mediated gene correction using single AAV vector transduction and enhancement by Food and Drug Administration-approved drugs. Gene Ther 2013; 20:35-42.
53. Li H, Haurigot V, Doyon Y, et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 2011; 475:217-221.
54. Hausl MA, Zhang W, Muther N, et al. Hyperactive sleeping beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B. Mol Ther 2010; 18:1896-1906.
55. Matsui H, Hegadorn C, Ozelo M, et al. A microRNA-regulated and GP64- pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of hemophilia A. Mol Ther 2011; 19:723-730.
56. Johnston JM, Denning G, Doering CB, et al. Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia A. Gene Ther 2012; 20:607-615.
57. Suwanmanee T, Hu G, Ma H, et al. Complete long-term correction of hemophilic B mice using integration-defective lentiviral vectors expressing codon-optimized R338L human factor IX. Mol Ther 2012; 20:S89.
58. Kuether EL, Schroeder JA, Fahs SA, et al. Lentivirus-mediated platelet gene therapy of murine hemophilia A with preexisting antifactor VIII immunity. J Thromb Haemost 2012; 10:1570-1580.
59. Zhang G, Shi Q, Fahs SA, et al. Factor IX ectopically expressed in platelets can be stored in alpha-granules and corrects the phenotype of hemophilia B mice. Blood 2010; 116:1235-1243.
60. Yakura Y, Ishihara C, Kurosaki H, et al. An induced pluripotent stem cellmediated and integration-free factor VIII expression system. Biochem Biophys Res Commun 2013; 431:336-341.
61. Ide LM, Iwakoshi NN, Gangadharan B, et al. Functional aspects of factor VIII expression after transplantation of genetically-modified hematopoietic stem cells for hemophilia A. J Gene Med 2010; 12:333-344.
62. Sun J, Hakobyan N, Valentino LA, et al. Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX. Blood 2008; 112:4532-4541.
63. Kashiwakura Y, Ohmori T, Mimuro J, et al. Intra-articular injection of mesenchymal stem cells expressing coagulation factor ameliorates hemophilic arthropathy in factor VIII-deficient mice. J Thromb Haemost 2012; 10:1802-1813.
64. Porada CD, Sanada C, Kuo CJ, et al. Phenotypic correction of hemophilia A in sheep by postnatal intraperitoneal transplantation of FVIII-expressing MSC. Exp Hematol 2011; 39:1124-1135.